

PE/Cy7 Anti-human CD11a Antibody *R7-1*Catalog number: 101141O0, 101141O1, 101141O2
Unit size: 25 tests, 100 tests, 500 tests**Product Details**

Storage Conditions	2-8°C with minimized light exposure. Do not freeze.
Expiration Date	12 months upon receiving
Concentration	0.1 mg/mL
Formulation	Phosphate-buffered saline (PBS, pH 7.2), 0.09% sodium azide, 0.2% (w/v) BSA

Antibody Properties

Species Reactivity	Human
Class	Primary
Clonality	Monoclonal
Host	Mouse
Isotype	Mouse igg1
Immunogen	CD11a (LFA-1A, Integrin α L, ITGAL)
Clone	R7-1
Conjugate	PE/Cy7

Biological Properties

Preparation	Antibody purified by affinity chromatography and then conjugated with PE/Cy7 under optimal conditions
Application	Flow Cytometry (FACS)

Spectral Properties

Conjugate	PE/Cy7
Excitation Wavelength	566 nm
Emission Wavelength	778 nm

Applications

R7-1 is an anti-human monoclonal antibody that forms an immune complex with the CD11a antigen. CD11a (alternatively called α L Integrin or Integrin α -L) is a 170 - 180 kD transmembrane glycoprotein that is found on the surface of cells like T cells, NK cells, macrophages, granulocytes and B cells. CD11a has been closely linked to critical biological processes like cell-cell adhesion, particularly leukocyte cell-cell adhesion. In addition, it is involved with key cellular pathways, in particular, the integrin-mediated signaling pathway. From a research standpoint, it is of biological interest due to its association with vital macromolecules/ligands like ICAM-1, 2, 3 and 4 and CD18. CD11a is a fairly uncommon antibody target, with a little more than 3700 publications in the last decade. Even still, CD11a is often used in flow cytometry applications as a phenotypic marker for differentiation of cell types, especially in the study of cell adhesion and immunology. This antibody was

purified through affinity chromatography and conjugated to PE/Cy7 (ex/em = 566/778 nm). It is compatible with the 561 nm laser and 780/60 nm bandpass filter (for example, as in the BD FACSAria™ Fusion).